DHDachuan Huang

Dachuan Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dachuan Huang has a total of 633 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference

    by Dachuan Huang, Wee Wei Tee, Sanjay De Mel, Koji Itahana, Kanaga Sabapathy, Kristijan Ramadan, Reshma Taneja, Giang Le Minh, Derrick Sek Tong Ong, Zhong Yi Yeow, et al.

    The 17th Annual Frontiers in Cancer Science (FCS) conference (2025) highlighted the convergence of multiomics, computational biology, and ancestry-specific genomics to advance proactive cancer care. Key insights included the role of epigenetic plasticity in maintaining tumor-propagating states and the identification of metabolic vulnerabilities, such as the WNK1–mTORC1 axis in leukemia and MAF-driven glutamine metabolism in myeloma. The meeting underscored the systemic nature of cancer, detailing how “cancer-educated” neutrophils prime premetastatic niches and how spatial exclusion mechanisms hinder immunotherapy. Breakthroughs in therapeutic engineering were showcased, including CD7-directed chimeric antigen receptor T cells and irreversible KRASG12C inhibitors. A critical focus remained on precision oncology for diverse populations, advocating for ancestry-aware datasets and long-read sequencing to address genomic disparities in Asian cohorts. Furthermore, the integration of artificial intelligence–driven “fragmentomics” and machine learning offers new pathways for early detection and tracking disease lethality. Collectively, FCS 2025 demonstrated that the future of oncology lies in integrating high-resolution disease models with robust data science to transition from reactive treatment to personalized, interceptive management.

  • Open Access

    Data from Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma

    by Cheng Huang, Yan Gao, Jianfeng Chen, Jing Han Hong, Yue Jiang, Kelila Xin Ye Chai, Yingxi Li, Peili Wang, Yali Wang, Jiuping Gao, et al.

    Anti–PD-1 immunotherapy has demonstrated significant antitumor efficacy in relapsed or refractory NK/T-cell lymphoma (R/R NKTL), but resistance remains a substantial challenge. In this study, we evaluate DNA methyltransferase (DNMT) inhibitors combined with anti–PD-1 mAb in 21 patients with R/R NKTL for whom prior immunotherapy failed. This combination therapy achieved an objective response rate of 66.7% (14/21), with a complete response rate of 47.6% (10/21) and a 2-year overall survival rate of 50.2%. Preclinical models revealed that anti–PD-1 resistance was linked to the absence of CD8+ T-cell infiltration and suppressed IFN pathways. DNMT inhibitors reversed these effects, restoring CD8+ T-cell activities and tumor sensitivity to PD-1 blockade. Mechanistically, DNMT inhibitors triggered DNA demethylation of endogenous retroviral elements, activating viral mimicry via upregulated endogenous nucleic acids and type I IFN signaling. These findings underscore DNMT inhibitors’ role in overcoming PD-1 resistance and support their combination with anti–PD-1 as a promising strategy for R/R NKTL.Significance:Resistance to anti–PD-1 immunotherapy remains a substantial challenge in R/R NKTL. In this study, we reported that combining DNMT inhibitors with anti–PD-1 mAb achieves a high complete response rate of 47.6% in immunotherapy-R/R NKTL patients. Mechanistically, DNMT inhibitors potentiate anti–PD-1 efficacy by triggering viral mimicry, remodeling the immune microenvironment and augmenting antitumor immunity.

  • Open Access

    Supplementary Tables S1-S4 from Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma

    by Cheng Huang, Yan Gao, Jianfeng Chen, Jing Han Hong, Yue Jiang, Kelila Xin Ye Chai, Yingxi Li, Peili Wang, Yali Wang, Jiuping Gao, et al.

    Supplementary Table S1 Table S1 Prior ICB treatment information of patients. Supplementary Table S2 Baseline characteristics of patients. Supplementary Table S3 Primers for DNA methylation analysis. Supplementary Table S4 Primers for RT-qPCR.

  • Open Access

    Supplementary Figures S1-12 from Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma

    by Cheng Huang, Yan Gao, Jianfeng Chen, Jing Han Hong, Yue Jiang, Kelila Xin Ye Chai, Yingxi Li, Peili Wang, Yali Wang, Jiuping Gao, et al.

    Supplementary Figure S1. Tumor-infiltrating CD8+ cell was positive correlation to efficacy of the combined DNMT inhibition and anti-PD-1 mAb therapy. Supplementary Figure S2. No significant reduction in body weight of EL4 tumor-bearing mice with anti-PD-1 treatment. Supplementary Figure S3. Gating strategies for Figure 2D-F. Supplementary Figure S4. PD-L1 and PD-1 expression in pre-clinical models. Supplementary Figure S5. Immune related pathways were downregulated in EL4 P3 tumor. Supplementary Figure S6. No significant reduction in body weight of EL4 P3 tumor-bearing mice under different treatment. Supplementary Figure S7. DNMT inhibitors enhance CD8+ T cell activated and cytotoxicity in vivo. Supplementary Figure S8. DNMT inhibitors treatment did not affect PD-L1 expression in pre-clinical models. Supplementary Figure S9. DNMT inhibitors induce MHC-I and ISGs expression in EL4 cells. Supplementary Figure S10. IFNAR1 blockade attenuated the antitumor immunity induced by the combination of DAC and α-PD-1. Supplementary Figure S11. STING knockdown did not impair DNMT inhibitors induced CD8+ T cells activity. Supplementary Figure S12. DNMT inhibitors induces ERVs expression in human NKTL cells.

  • Top Cited Papers
    Open Access

    Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma

    by Cheng Huang, Yan Gao, Jianfeng Chen, Jing Han Hong, Yue Jiang, Kelila Xin Ye Chai, Yingxi Li, Peili Wang, Yali Wang, Jiuping Gao, et al.

    Anti–PD-1 immunotherapy has demonstrated significant antitumor efficacy in relapsed or refractory NK/T-cell lymphoma (R/R NKTL), but resistance remains a substantial challenge. In this study, we evaluate DNA methyltransferase (DNMT) inhibitors combined with anti–PD-1 mAb in 21 patients with R/R NKTL for whom prior immunotherapy failed. This combination therapy achieved an objective response rate of 66.7% (14/21), with a complete response rate of 47.6% (10/21) and a 2-year overall survival rate of 50.2%. Preclinical models revealed that anti–PD-1 resistance was linked to the absence of CD8+ T-cell infiltration and suppressed IFN pathways. DNMT inhibitors reversed these effects, restoring CD8+ T-cell activities and tumor sensitivity to PD-1 blockade. Mechanistically, DNMT inhibitors triggered DNA demethylation of endogenous retroviral elements, activating viral mimicry via upregulated endogenous nucleic acids and type I IFN signaling. These findings underscore DNMT inhibitors’ role in overcoming PD-1 resistance and support their combination with anti–PD-1 as a promising strategy for R/R NKTL. Significance: Resistance to anti–PD-1 immunotherapy remains a substantial challenge in R/R NKTL. In this study, we reported that combining DNMT inhibitors with anti–PD-1 mAb achieves a high complete response rate of 47.6% in immunotherapy-R/R NKTL patients. Mechanistically, DNMT inhibitors potentiate anti–PD-1 efficacy by triggering viral mimicry, remodeling the immune microenvironment and augmenting antitumor immunity.


  • Open Access

    Correspondence: Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma

    by Jing Quan Lim, Dachuan Huang, Choon Kiat Ong

    Recurrent somatic mutation in the ECSIT gene encoding p.V140A was reported in 19.3% (17/88) extranodal natural-killer/T cell lymphoma (ENKTL) and was associated with hemophagocytic syndrome (HPS). However, another cohort of similar geographical descent also had the ECSIT V140A mutation as germline in 20.0% (5/25) of ENKTL and none were somatic. The reanalysis of published data revealed that the reported somatic ECSIT V140A could be germline as well. First-digit analysis on the IDs of sequencing read also found irregularity among the data that initially reported the somatic ECSIT V140A mutation. As such, this study questions the only somatic genetic link of HPS in ENKTL and also introduces a simple well-known algorithm to detect data irregularity in voluminous genomic sequencing data.

  • ASTER: A Method to Predict Clinically Relevant Synthetic Lethal Genetic Interactions

    by Herty Liany, Aishwarya Jayagopal, Dachuan Huang, Jing Quan Lim, Nur Izzah Nbh, Anand Jeyasekharan, Choon Kiat Ong, Vaibhav Rajan

    A Synthetic Lethal (SL) interaction is a functional relationship between two genes or functional entities where the loss of either entity is viable but the loss of both is lethal. Such pairs can be used to develop targeted anticancer therapies with fewer side effects and reduced overtreatment. However, finding clinically relevant SL interactions remains challenging. Leveraging unified gene expression data of both disease-free and cancerous samples, we design a new technique based on statistical hypothesis testing, called ASTER, to identify SL pairs. We empirically find that the patterns of mutually exclusivity ASTER finds using genomic and transcriptomic data provides a strong signal of synthetic lethality. For large-scale multiple hypothesis testing, we develop an extension called ASTER++ that can utilize additional input gene features within the hypothesis testing framework. Our computational and functional experiments demonstrate the efficacy of ASTER in identifying SL pairs with potential therapeutic benefits.


  • An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma

    by Jasmine Goh, Sanjay De Mel, Michal M. Hoppe, Masturah Bte Mohd Abdul Rashid, Xi Yun Zhang, Patrick Jaynes, Esther Ka Yan Ng, Nur’aTiqa Diana Binti Rahmat, Jayalakshmi, Clementine Xin Liu, et al.

    Although combination therapy is the standard of care for relapsed/refractory non-Hodgkin’s lymphoma (RR-NHL), combination treatment chosen for an individual patient is empirical, and response rates remain poor in individuals with chemotherapy-resistant disease. Here, we evaluate an experimental-analytic method, quadratic phenotypic optimization platform (QPOP), for prediction of patient-specific drug combination efficacy from a limited quantity of biopsied tumor samples. In this prospective study, we enrolled 71 patients with RR-NHL (39 B cell NHL and 32 NK/T cell NHL) with a median of two prior lines of treatment, at two academic hospitals in Singapore from November 2017 to August 2021. Fresh biopsies underwent ex vivo testing using a panel of 12 drugs with known efficacy against NHL to identify effective single and combination treatments. Individualized QPOP reports were generated for 67 of 75 patient samples, with a median turnaround time of 6 days from sample collection to report generation. Doublet drug combinations containing copanlisib or romidepsin were most effective against B cell NHL and NK/T cell NHL samples, respectively. Off-label QPOP-guided therapy offered at physician discretion in the absence of standard options ( n = 17) resulted in five complete responses. Among patients with more than two prior lines of therapy, the rates of progressive disease were lower with QPOP-guided treatments than with conventional chemotherapy. Overall, this study shows that the identification of patient-specific drug combinations through ex vivo analysis was achievable for RR-NHL in a clinically applicable time frame. These data provide the basis for a prospective clinical trial evaluating ex vivo–guided combination therapy in RR-NHL.


  • Open Access

    DDX3X Loss is Associated with Aggressive Phenotypes in Non-Hodgkin’s Lymphomas

    by Atish Kizhakeyil, Nurmahirah Binte Mohammed Zaini, Zhi Sheng Poh, Brandon Han Siang Wong, Xinpeng Loh, Aik Seng Ng, Zun Siong Low, Praseetha Prasannan, Jade Gong, Michelle Guet Khim Tan, et al.

    Non-Hodgkin’s lymphoma (NHL) is a diverse group of malignancies, encompassing the most common diffuse large B-cell lymphoma (DLBCL) to the rarer T-cell lymphomas. DDX3X is an RNA helicase and, depending on tumour type, plays tumour suppressive or oncogenic roles in cancer. However, its role in NHL is not clear. Targeted sequencing of DDX3X hotspots on exons 8-15 in a cohort of 158 unselected DLBCL subjects showed DDX3X mutations in 5 cases; whereas whole exome sequencing in a cohort of 9 relapsed/refractory DLBCL patients treated with R-CHOP identified DDX3X mutations in 4 cases. DLBCL patients (n=223) with DDX3X mutations had worse 5-year overall survival (22%) compared to patients with wild-type DDX3X (72%, p=0.021). Using DLBCL and cutaneous T-cell lymphoma (CTCL) cell lines, we showed that the expression of mutant DDX3X-R475C or DDX3X knockdown significantly enhanced cell migratory/invasive potential and elevated the phosphorylation of STAT3, Akt and p42/44. DDX3X loss increased resistance to doxorubicin and histone deacetylase targeting drugs in DLBCL and CTCL cells, respectively. Importantly, B- and T-cell lineage DDX3X-depleted cells remained sensitive to STAT3 inhibition. We conclude that DDX3X mutations are important driver lesions in NHL subtypes and are associated with chemoresistance but may be countered with a STAT3 inhibitor.

  • Top Cited Papers
    Open Access

    Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma

    by Jason Yongsheng Chan, Jing Quan Lim, Joe Yeong, Vinod Ravi, Peiyong Guan, Arnoud Boot, Timothy Kwang Yong Tay, Sathiyamoorthy Selvarajan, Nur Diyana Md Nasir, Jie Hua Loh, et al.

    Angiosarcomas are rare, clinically aggressive tumors with limited treatment options and a dismal prognosis. We analyzed angiosarcomas from 68 patients, integrating information from multiomic sequencing, NanoString immuno-oncology profiling, and multiplex immunohistochemistry and immunofluorescence for tumor-infiltrating immune cells. Through whole-genome sequencing (n = 18), 50% of the cutaneous head and neck angiosarcomas exhibited higher tumor mutation burden (TMB) and UV mutational signatures; others were mutationally quiet and non–UV driven. NanoString profiling revealed 3 distinct patient clusters represented by lack (clusters 1 and 2) or enrichment (cluster 3) of immune-related signaling and immune cells. Neutrophils (CD15+), macrophages (CD68+), cytotoxic T cells (CD8+), Tregs (FOXP3+), and PD-L1+ cells were enriched in cluster 3 relative to clusters 2 and 1. Likewise, tumor inflammation signature (TIS) scores were highest in cluster 3 (7.54 vs. 6.71 vs. 5.75, respectively; P < 0.0001). Head and neck angiosarcomas were predominant in clusters 1 and 3, providing the rationale for checkpoint immunotherapy, especially in the latter subgroup with both high TMB and TIS scores. Cluster 2 was enriched for secondary angiosarcomas and exhibited higher expression of DNMT1, BRD3/4, MYC, HRAS, and PDGFRB, in keeping with the upregulation of epigenetic and oncogenic signaling pathways amenable to targeted therapies. Molecular and immunological dissection of angiosarcomas may provide insights into opportunities for precision medicine.